Common Stock, no par value per share
- Symbol
- TMDX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
TransMedics Group, Inc.
TMDXNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 4, 2026, TransMedics Group, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2026. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.…
Press release in this filing
TransMedics Reports Second Quarter 2026 Financial Results →Company context
TransMedics is the world’s leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Current securities
Registered securities in this filing
TransMedics Group, Inc. · 8-K · Filed 2026-08-04
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On August 4, 2026, TransMedics Group, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2026. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
The information in this Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 2 tmdx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 TransMedics Reports Second Quarter 2026 Financial Results Andover, Mass. - August 4, 2026 - TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2026. Recent Highlights ▪ Total revenue of $189.9 million in the second quarter of 2026, a 21% increase compared to the second quarter of 2025 ▪ Product revenue of $111.2 million, up 16% and Service revenue of $78.8 million, up 29% ▪ Net income of $14.7 million or $0.41 per fully diluted share in the second quarter of 2026 ▪ Adjusted net income of $16.2 million or $0.44 per fully diluted share in the second quarter of 2026 ▪ Raised low end of full-year 2026 revenue guidance, excluding PAD Aviation, to a range of $737 million to $757 million ▪ On July 1, 2026, completed its strategic investment in PAD Aviation, a premier Germany-based private aviation operator, as the first step to establishing a dedicated organ transplantation air logistics network across Europe, and beyond…
Open exhibit ↗